Asthma
Conditions
Brief summary
The project aims to investigate the effect of female sex hormone treatment (both contraceptive treatment and hormone therapy during menopause) on bronchial hyperreactivity in adult women. The study is a prospective cohort study involving 300 women, examining airway responsiveness before and after the initiation of hormone treatment, whether as hormone therapy in menopause or contraceptive treatment. Participants will be recruited from general practitioners in the Capital Region of Denmark. Lung function, bronchial hyperreactivity, airway inflammation, and body composition will be assessed before and after hormone treatment. Blood samples will also be collected and stored for later analysis of inflammation markers. The study will include women aged 18 to 75 who are about to begin hormone treatment.
Interventions
Women initiating either Hormonal Contraceptives or Hormone replacement therapy in menopause
Sponsors
Copenhagen University Hospital, Hvidovre
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Women aged 18 to 75 years * Planning to initiate HRT/HC within next 30 days
Exclusion criteria
* Gynecological, endocrinological or other disease affecting the ovarian cycle * FEV1 \< 60% of expected or \< 1.5L * Current hormonal medication * Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Airway responsiveness to methacholine | 30 to 14 days before initiation of HC/HRT and 7-14 days and 42-56 days following initiation | Airway responsiveness to methacholine challenge before and after initiation of HC/HRT treatment reported as a dose-response-ratio defined as change in %FEV1 per μmol |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline as measured by airway oscillometry (AOS) | 30 to 14 days before initiation of HC/HRT and 7-14 days and 42-56 days following initiation |
| Changes in airway inflammation measured as FeNO | 30 to 14 days before initiation of HC/HRT and 7-14 days and 42-56 days following initiation |
| Changes in blood alarmins such as blood eosinophils, interleukin 4 (IL-4), IL-5, IL-6, IL-8, IL-10, IL-13, IL-17, IL-23, IL-33, TSLP, IL-1 and Tumor Necrosis Factor alfa (TNF-alfa) | 30 to 14 days before initiation of HC/HRT and 7-14 days and 42-56 days following initiation |
| Medical Research Council Dyspnea Scale (MRC) will be used to evaluate subjective dyspnea. MRC will be evaluated by medical interview. | 30 to 14 days before initiation of HC/HRT and 7-14 days and 42-56 days following initiation |
| Changes in lung function measured as forced expiratory volume in first second (FEV1), forced vital capacity (FVC), | 30 to 14 days before initiation of HC/HRT and 7-14 days and 42-56 days following initiation |
| Changes in body composition - fat distribution | 30 to 14 days before initiation of HC/HRT and 7-14 days and 42-56 days following initiation |
| Changes in body composition measured as fat percent | 30 to 14 days before initiation of HC/HRT and 7-14 days and 42-56 days following initiation |
| Changes in body composition measured as fat mass (kg) | 30 to 14 days before initiation of HC/HRT and 7-14 days and 42-56 days following initiation |
| Baseline Dyspnea Index (BDI) will be used to evaluate subjective dyspnea. Will be evaluated by medical interview. | 30 to 14 days before initiation of HC/HRT and 7-14 days and 42-56 days following initiation |
| Changes in allergy measured as skin prick test (SPT) to common inhaled allergens | 30 to 14 days before initiation of HC/HRT and 7-14 days and 42-56 days following initiation |
Contacts
Primary ContactErik SH Hansen, MD, PHD
Outcome results
None listed